deaths (OS)

metastatic/advanced OC (mOC) - 2nd line (L2) metastatic/advanced OC (mOC) - 2nd line (L2)

versus nivolumab alone
nivolumab plus ipilimumab vs. nivolumab alone 1 -420 [-2369; 1528] /10000
21/49 vs. 24/51